Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial-Reference-Cited by-同舟云学术

Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

Published:2019-08-13 Issue:12 Volume:35 Page:2079-2087
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Reyes Adriana¹,Révil Cédric¹,Niggli Markus¹,Chebon Sammy¹,Schlagmüller Simone²,Flacke Jan-Paul²,Zortel Max²,Paz-Priel Ido³,Asikanius Elina¹,Hampton Roger¹,Mahajan Anadi⁴,Schmidt Elvira⁵,Edwards Susan C.¹

Affiliation:

1. F. Hoffmann-La Roche, Basel, Switzerland;

2. Roche Pharma AG, Grenzach-Wyhlen, Germany;

3. Genentech, San Francisco, CA, USA;

4. Bridge Medical, New Delhi, India;

5. Certara, Lörrach, Germany (formerly Analytica Laser)

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1649378

Reference43 articles.

1. Centers for Disease Control and Prevention [Internet]. Data & statistics on hemophilia; 2018. Sep 6 [cited 2019 Mar]. Available from: https://www.cdc.gov/ncbddd/hemophilia/data.html.

2. National Heart, Lung, and Blood Institute [Internet]. Hemophilia: what is; 2013. [cited 2019 Mar]. Available from: www.nhlbi.nih.gov/health/health-topics/topics/hemophilia/.

3. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

4. Quality of life in haemophilia A: Hemophilia Utilization Group Study Va (HUGS-Va)

5. Musculoskeletal Complications of Hemophilia

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced doses of emicizumab achieve good efficacy: Results from a national‐wide multicentre real‐world study in China;Haemophilia;2024-06-09

2. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

3. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

4. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A;Blood Reviews;2023-12

5. Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis;Haemophilia;2023-06-22